185 related articles for article (PubMed ID: 20207580)
21. Epigenetic cancer therapy: rationales, targets and drugs.
Rius M; Lyko F
Oncogene; 2012 Sep; 31(39):4257-65. PubMed ID: 22179827
[TBL] [Abstract][Full Text] [Related]
22. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Hess-Stumpp H
Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
[TBL] [Abstract][Full Text] [Related]
24. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
25. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
28. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
[TBL] [Abstract][Full Text] [Related]
29. Targeting class I histone deacetylases in cancer therapy.
Delcuve GP; Khan DH; Davie JR
Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulatory mechanisms of histone acetylation in the treatment of cutaneous squamous cell carcinoma.
Joshi TP; Farr MA; Lewis DJ
Expert Opin Ther Targets; 2021 Nov; 25(11):1025-1026. PubMed ID: 34814792
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
Weïwer M; Lewis MC; Wagner FF; Holson EB
Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of histone deacetylases.
Huang Y; Shaw PG; Davidson NE
Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
35. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
Zhang S; Zhan L; Li X; Yang Z; Luo Y; Zhao H
Int J Biol Sci; 2021; 17(13):3381-3400. PubMed ID: 34512154
[TBL] [Abstract][Full Text] [Related]
36. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
39. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
Gomazkov OA
Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
